Shanghai-headquartered biopharmaceutical group Junshi Biosciences has scheduled a board meeting for Monday, 27 April 2026. Directors will review and approve the Group’s unaudited financial results for the three-month period ended 31 March 2026.

The notice, dated 15 April 2026, specifies that Chairman Mr. Xiong Jun will preside over the session. The Board currently comprises eight executive directors (including Mr. Xiong Jun and Dr. Li Ning), one non-executive director, and five independent non-executive directors.

The forthcoming disclosure of first-quarter numbers will provide investors and stakeholders with the latest operational and financial metrics following the close of the reporting period.